



Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,
 Rasoolpura, Secunderabad - 500 003, INDIA.
 Tel : +91 40 6657 5454, 2790 3226
 Fax : +91 40 2790 8708
 Website : www.vantabio.com
 Email : info@vantabio.com
 CIN No. : U74999TG2016PLC109280

To,
 The Listing Department,
 BSE Ltd.

July 27, 2018

Sub: Outcome of Board Meeting held on July 27, 2018.

We wish to inform you that the Board Directors of the Company, at their just concluded meeting have considered and approved to foray into clinical research business.

Accordingly, the Board has decided to do the following in this connection:

- 1) To incorporate a 100% subsidiary in the name of "Vanta Clinical Research Limited" (or such other name as approved by CRC, Delhi) at Hyderabad.
- 2) To incorporate a 51% step down subsidiary of the above mentioned Company in the name of "Vayam Research Solutions Limited" (or such other name as approved by CRC, Delhi) at Hyderabad.

The details as required under SEBI (LODR) Regulations, 2015 read with SEBI Circular No CIR/CFD/CMD/4/2015 dated September 09, 2015 are given as under:

S. No	Particulars	Details
1	Name of the Target entity, details in brief such as size, turnover etc.,	Incorporation of 100 % subsidiary and 51% step down subsidiary by name Vanta Clinical Research Limited and Vayam Research Solutions Limited respectively. <i>(or such other name as approved by CRC, Delhi)</i>
2	Whether the acquisition would fall within the related party transaction and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length";	Our Company is incorporating the above mentioned companies as subsidiaries - Once incorporated, these companies will become related parties to the Company.



Research Center :
 K2-B, 11th Cross Street, SIPCOT Industrial Complex,
 Gummidipoondi, Thiruvallur District, Tamilnadu - 601 201.
 Tel : 044 6700 1500

		<p>The Board has approved making investments in the equity shares of these Companies in the manner as mentioned above.</p> <p>The shares shall be subscribed at face value and thus can be considered at arms' length.</p>
3	Industry to which the entity being acquired belongs	Clinical Research
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	<p>Both the subsidiaries are being incorporated in line with Company's plan to foray into Clinical Business.</p> <p>Object will be Clinical Research</p>
5	Brief details of any governmental or regulatory approvals required for the acquisition;	-NA-
6	Indicative time period for completion of the acquisition;	<p>-NA-</p> <p>(Incorporation of subsidiary and step down subsidiary of our Company)</p>
7	Nature of consideration - whether cash consideration or share swap and details of the same	The initial subscription amount/remittance shall be in the form of cash/bank
8	Cost of acquisition or the price at which the shares are acquired;	shall be at face value as these are newly incorporated companies
9	Percentage of shareholding/ control acquired and/ or number of shares acquired;	<p>100% & 51%</p> <p>(Subsidiary and Step Down Subsidiary of Vanta Bioscience Limited)</p>
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>Both the subsidiaries are being incorporated in line with Company's plan to foray into Clinical Business.</p> <p>Object will be Clinical Research</p>



The meeting commenced at 11.30 A.M. and concluded at 6.15 P.M.

This for your information and dissemination to the public.

For VANTA BIOSCIENCE LIMITED
Scrip Code: 540729 | Scrip ID: VANTABIO

S. Venkate
SADHANALA VENKATA RAO
CEO & Whole Time Director
DIN: 02906370

